CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Takhzyro lanadelumab Hereditary angioedema, prevention Reimburse with clinical criteria and/or conditions Complete
Taltz ixekizumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete
Taltz Ixekizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Taltz ixekizumab Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Talzenna talazoparib Breast Cancer Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Talzenna talazoparib Metastatic castration-resistant prostate cancer (mCRPC) Suspended
Tarceva Erlotinib Cancer, Lung , non-small cell List with clinical criteria and/or conditions Complete
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled
Targin Oxycodone HCI / naloxone HCI Pain, moderate to severe and relief of opioid-induced constipation Do not list Complete
Tavalisse fostamatinib Chronic immune thrombocytopenia Do not reimburse Complete
Tavneos avacopan Antineutrophil cytoplasmic antibody-associated vasculitis Do not reimburse Complete
TBC risperidone Schizophrenia, adults Suspended
TBC ruxolitinib atopic dermatitis Active
TBC pegcetacoplan Geographic atrophy secondary to age-related macular degeneration Active
TBC abaloparatide Osteoporosis, postmenopausal women Withdrawn
TBC tirzepatide Diabetes mellitus, type 2 Cancelled
TBC talquetamab Relapsed or refractory multiple myeloma Active
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled
TBC filgrastim Cancelled
TBC blinatumomab B-cell precursor acute lymphoblastic leukemia Pending
TBC teprotumumab Thyroid Eye Disease (TED), acute Pending
TBC teprotumumab Thyroid Eye Disease (TED), chronic Pending
TBC omaveloxolone Friedrich’s ataxia Pending
TBC crovalimab paroxysmal nocturnal hemoglobinuria (PNH) Pending
TBC ruxolitinib Nonsegmental vitiligo Pending
Last Updated : September 20, 2024